secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2022-09-29T23:59:59+00:00
Accession:  0001493152-22-027121
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa Biosciences reports favorable safety and stable tumor lesions in first patient of CAR-T trial
--------------------------------------------------------------------------------

- First patient treated in chimeric endocrine receptor T-cell (CAR-T) clinical trial shows favorable safety signals.
- Imaging at one month post-treatment indicates tumor lesions are stable and not growing.
- Patient appears to be doing well and will continue to be monitored; enrollment continues.
- Data presented by inventor Dr. Jose Conejo-Garcia at AACR/Rivkin Ovarian Cancer Symposium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315222027121/0001493152-22-027121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315222027121/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-027121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer